AGP Executive Report
Last update: 10 hours agoBiotech Deal: Innovent Biologics and Pfizer signed a global licensing and collaboration pact worth up to $10.5bn to develop 12 early-stage cancer medicines, with Innovent leading Phase 1 and keeping Greater China rights. Marine Pharma Policy: China issued its first national policy for marine biopharmaceuticals, targeting multiple new marine drugs and pushing industry value-added above CNY130bn by 2030. Maternal Emergency Care: A pregnant woman in Shandong gave up her operating room slot to a bleeding patient, a viral “life-and-death relay” highlighting hospital triage under pressure. Patient Experience Focus: A Prudential Health Summit in Hong Kong emphasized better coordination across insurers, providers, and regulators to improve how patients navigate care. Access to Medicines: Cyprus reported limited availability of innovative EU medicines (66 of 168 from 2021–2024), underscoring ongoing gaps in getting new treatments to patients. Public Health & Policy: China tightened rules on online prescription drug sales and AI use in prescriptions, while also strengthening legal protection for minors with disabilities through case-based supervision. Regional Health Cooperation: China and Kyrgyzstan held regular political dialogue covering trade, culture, people-to-people ties, and healthcare cooperation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
